ARNA - アリ―ナ・ファ―マシュ―ティカルズ (Arena Pharmaceuticals Inc.) アリ―ナ・ファ―マシュ―ティカルズ

 ARNAのチャート


 ARNAの企業情報

symbol ARNA
会社名 Arena Pharmaceuticals Inc (アリ―ナ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アリーナ・ファーマシューティカルズ(Arena Pharmaceuticals Inc.)はバイオ医薬品会社である。同社は治療領域にわたって小分子薬物の開発に従事する。同社は、潰瘍性大腸炎の第II相評価におけるエトラサモード(APD334)、クローン病に関連する疼痛の治療のための第II相評価に入るAPD371、及び肺動脈性高血圧(PAH)の第II相評価におけるralinepag(APD811)の3つの主要治験臨床プログラムを有する。同社の医薬品であるLorcaserinは、体重管理の指標として米国と韓国で販売承認を受ける。同社の臨床開発における候補者には、自己免疫疾患のためのAPD334、血管疾患のためのralinepag及び疼痛のためのAPD371が含まれる。同社の協力プログラムには、認知症関連精神病のネロタンセリン、血栓性疾患のテマノグレル、中枢神経系(CNS)適応症の非公開孤児GPCRが含まれる。   アリ―ナ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。医薬品医療ニ―ズに対応するため、Gタンパク質共役型受容体を標的とする薬剤を開発、商品化する。同社が開発した肥満症治療剤「BELVIQ」は、米国食品医薬品局(FDA)に唯一承認された薬剤である。そのほか、肺動脈高血圧症の治療のためのAPD811など、研究開発中の薬剤候補がある。   
本社所在地 6154 Nancy Ridge Drive San Diego CA 92121 USA
代表者氏名 Tina Susan Nova ティナ・スーザン・ノヴァ
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-453-7200
設立年月日 35521
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 106人
url www.arenapharm.com
nasdaq_url https://www.nasdaq.com/symbol/arna
adr_tso
EBITDA EBITDA(百万ドル) -98.92900
終値(lastsale) 39.7
時価総額(marketcap) 1959123103.3
時価総額 時価総額(百万ドル) 1962.084
売上高 売上高(百万ドル) 13.97000
企業価値(EV) 企業価値(EV)(百万ドル) 1429.45
当期純利益 当期純利益(百万ドル) -112.12500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arena Pharmaceuticals Inc. revenues increased 62% to $5.7M. Net loss before extraordinary items increased 38% to $63M. Revenues reflect Royalty revenue increase from $0K to $1.6M Collaboration and other revenue increase of 17% to $4.2M. Higher net loss reflects Research and development increase of 39% to $44.7M (expense) General and administrative - increase of 41% to $16.6M (expense).

 ARNAのテクニカル分析


 ARNAのニュース

   Anti-obesity Drugs Market: The Next Big Innovation in Machinery Industry 2020||Novo Nordisk, Pfizer, Arena Pharmaceuticals, Roche  2020/12/15 08:14:05 OpenPR
The global Anti-obesity Drugs market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future
   Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference  2020/12/11 14:00:00 PR Newswire
SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in…
   Cannabis Stock Gainers And Losers From December 8, 2020  2020/12/08 22:02:21 Benzinga
GAINERS: iAnthus Capital Hldgs (PINK: ITHUF ) shares closed up 24% at $0.31 22nd Century Group, Inc. Common Stock (AMEX: XXII) shares closed up 21.15% at $1.89 C21 Investments (OTCQX: CXXIF ) shares closed up 12.31% at $1.15 EnWave (PINK: NWVCF ) shares closed up 12.09% at $1.02 Bloom Energy (NYSE: BE ) shares closed up 10.83% at $30.60 Zelira Therapeutics (OTCQB: ZLDAF ) shares closed up 6.78% at $0.06 Cannabics Pharmaceuticals (OTCQB: CNBX ) shares closed up 4.73% at $0.32 Arena Pharmaceuticals (NASDAQ: ARNA ) shares closed up 3.78% at … Full story available on Benzinga.com
   Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial  2020/12/08 13:30:00 PR Newswire
SAN DIEGO, Dec. 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has achieved its targeted enrollment goal of 372 participants in the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of once-daily etrasimod, a highly selective,…
   Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1  2020/11/24 13:30:00 PR Newswire
SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on…
   Anti-obesity Drugs Market: The Next Big Innovation in Machinery Industry 2020||Novo Nordisk, Pfizer, Arena Pharmaceuticals, Roche  2020/12/15 08:14:05 OpenPR
The global Anti-obesity Drugs market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future
   Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference  2020/12/11 14:00:00 PR Newswire
SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in…
   Cannabis Stock Gainers And Losers From December 8, 2020  2020/12/08 22:02:21 Benzinga
GAINERS: iAnthus Capital Hldgs (PINK: ITHUF ) shares closed up 24% at $0.31 22nd Century Group, Inc. Common Stock (AMEX: XXII) shares closed up 21.15% at $1.89 C21 Investments (OTCQX: CXXIF ) shares closed up 12.31% at $1.15 EnWave (PINK: NWVCF ) shares closed up 12.09% at $1.02 Bloom Energy (NYSE: BE ) shares closed up 10.83% at $30.60 Zelira Therapeutics (OTCQB: ZLDAF ) shares closed up 6.78% at $0.06 Cannabics Pharmaceuticals (OTCQB: CNBX ) shares closed up 4.73% at $0.32 Arena Pharmaceuticals (NASDAQ: ARNA ) shares closed up 3.78% at … Full story available on Benzinga.com
   Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial  2020/12/08 13:30:00 PR Newswire
SAN DIEGO, Dec. 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has achieved its targeted enrollment goal of 372 participants in the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of once-daily etrasimod, a highly selective,…
   Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1  2020/11/24 13:30:00 PR Newswire
SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on…
   Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1  2020/11/24 13:30:00 PR Newswire
SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on…
   Arena Pharmaceuticals (NASDAQ:ARNA) Receives New Coverage from Analysts at Smith Barney Citigroup  2020/11/20 13:04:47 Transcript Daily
Smith Barney Citigroup assumed coverage on shares of Arena Pharmaceuticals (NASDAQ:ARNA) in a research report sent to investors on Thursday, The Fly reports. The brokerage issued an outperform rating and a $100.00 target price on the biopharmaceutical company’s stock. Other equities research analysts also recently issued reports about the company. HC Wainwright reaffirmed a buy […]
   Arena Pharmaceuticals (NASDAQ:ARNA) Now Covered by Analysts at Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell  2020/11/20 13:04:46 Transcript Daily
Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell began coverage on shares of Arena Pharmaceuticals (NASDAQ:ARNA) in a research note published on Thursday morning, Stock Target Advisor reports. The firm issued an outperform rating and a $100.00 target price on the biopharmaceutical company’s stock. Several other equities research analysts also recently issued reports […]
   Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis  2020/11/09 21:05:00 PR Newswire
SAN DIEGO, Calif., Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2020. "Over the quarter we made significant progress across our pipeline – most importantly…
   Arena Pharmaceuticals Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2020/11/09 12:33:00 Stock Market Daily
Arena Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アリ―ナ・ファ―マシュ―ティカルズ ARNA Arena Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)